-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States -- SAN DIEGO, June 11, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39336 Aditxt, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3204328 ...

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: Received $1 million from Aditxt, Inc. (Nasdaq: ADTX) in May 2024 in consideration for reinstating and amending the Merger Agreement, as amended, between the companies. Aditxt agreed t ...

Financial Performance and Funding - The company has generated no significant revenue from commercial sales to date, and future profitability remains uncertain[7] - The company may need to raise additional funding, which may not be available on acceptable terms, or at all[7] - The company is subject to risks including the need for additional funding, which may not be available on acceptable terms[7] Regulatory and Compliance - The regulatory approval process is expensive, time-consuming, and uncertain, potentially hindering the commercialization of future product candidates[7] - The company has regained compliance with Nasdaq continued listing requirements but remains subject to a panel monitor until December 29, 2024[8] - The company is actively involved in the regulatory approval process for AditxtScore assays and securing partnerships for market application[22] Innovation and Development - The company plans to continue building its infrastructure and securing more personalized and precision health innovations year over year[14] - The company is focused on developing health diagnostics and treatments that prioritize personalized precision medicine[14] - The company has built a systemized approach to innovation, encompassing innovation, operations, commercialization, and finance[12] - The company aims to bring in future health innovations in software, AI, medical devices, and therapeutics to enhance personalized precision medicine[14] - The company has established a systemized approach to the innovation process, which includes large-scale automation and enterprise systems for portfolio companies[14] Partnerships and Collaborations - The company has established partnerships with leading health institutions, such as Mayo Clinic, to facilitate critical trials[11] - The company has a business model focused on securing, growing, and monetizing innovations through partnerships with research institutions and health organizations[11] - The company aims to create a collaborative ecosystem where all stakeholders contribute to accelerate breakthrough innovations[13] Product Development and Trials - Adimune's product ADI-100 has been successfully tested in several preclinical models, including skin grafting and sclerosis[15] - A human trial for Stiff Person Syndrome (SPS) is expected to enroll 15 patients, pending regulatory approval, focusing on safety and efficacy of ADI-100[15] - AditxtScore technology provides a personalized immune system profile and is designed to detect individual immune responses to various agents[22] - AditxtScore assays can provide results in approximately 3-16 hours, with the ability to test for cellular immune responses[23] - ADI technology aims to retrain the immune system to accept transplanted organs with significantly reduced immune suppression[16] Market Potential and Strategic Transactions - Pearsanta aims to develop a platform for lab-quality testing, with the clinical and consumer diagnostic market projected to reach $429.3 billion by 2030[21] - The company entered into an Asset Purchase Agreement to acquire a 50% ownership interest in G Response Aid FZE for $24.5 million, including $10 million in cash[26] - The acquisition includes an exclusive worldwide license for the antiviral medication Avigan® 200mg, excluding Japan, China, and Russia[26] - The company aims to engage in future acquisitions or strategic transactions, which may require additional financing and increase expenses[8] Employee Relations - As of December 31, 2023, the company has forty-seven (47) full-time employees[29] - The company considers its relations with employees to be good[29]

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. (“Pearsanta”), has acquired MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precisio ...

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrants in lieu thereof) and accompanying wa ...

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1), subject to a mandatory panel monitor until December 29, 2024. This development is particularly significant ...

Group 1 - Proactive Investors specializes in providing fast, accessible, and informative business and finance news content to a global investment audience [1][2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [2] Group 2 - Proactive is committed to adopting technology to enhance content creation and workflow efficiency [2] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [2]

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a priv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39336 Aditxt, Inc. (Exact name of registrant as specified in its charter) Delaware 82-320 ...